Figures & data
Figure 1 Included patients.
![Figure 1 Included patients.](/cms/asset/7b0e05de-0e83-43fb-a058-714ad4d4966c/dcpa_a_12164191_f0001_b.jpg)
Table 1 Characteristics of the Patients Evaluable for Toxicity
Figure 2 Duration of treatment.
![Figure 2 Duration of treatment.](/cms/asset/ef6d6c3c-e0cf-4d16-9eb0-1eee55b78770/dcpa_a_12164191_f0002_c.jpg)
Table 2 Severe Toxicities Related to Oral Docetaxel Co-Administrated with Ritonavir
Figure 3 Correlation of the Cmax and the AUC of docetaxel.
![Figure 3 Correlation of the Cmax and the AUC of docetaxel.](/cms/asset/a6585489-368f-44d0-8eff-2424832a74a6/dcpa_a_12164191_f0003_b.jpg)
Figure 4 Relation of the exposure to ritonavir versus docetaxel.
![Figure 4 Relation of the exposure to ritonavir versus docetaxel.](/cms/asset/ba45477f-498c-4e58-8efc-8cf02da99962/dcpa_a_12164191_f0004_b.jpg)
Figure 5 Pharmacokinetic exposure to docetaxel in patients with and without severe toxicity.
![Figure 5 Pharmacokinetic exposure to docetaxel in patients with and without severe toxicity.](/cms/asset/9dd83f07-1d1b-48b5-a91e-b45500cb0309/dcpa_a_12164191_f0005_c.jpg)